- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06075953
DCIS: RECAST-Studie zum Duktalkarzinom in situ: Neubewertung der Bedingungen für die Eignung einer aktiven Überwachung als Behandlung
DCIS: RECAST-Studie – Duktales Karzinom in situ: Neubewertung der Bedingungen für die Eignung einer aktiven Überwachung als Behandlung: eine Pilotstudie zur Brustkrebsprävention
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.
Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.
Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:
- Provide blood sample to understand their immune status
- Provide saliva sample for genetic testing
- Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Participants will be followed annually for 10 years.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Tammy Neseth, MA, CCRP
- Telefonnummer: +1 (507) 269-8060
- E-Mail: t.neseth@qlhc.org
Studieren Sie die Kontaktsicherung
- Name: Sabrina Mayhew, Ph.D. Nursing
- Telefonnummer: +1 (888) 282-7099
- E-Mail: s.mayhew@qlhc.org
Studienorte
-
-
California
-
Berkeley, California, Vereinigte Staaten, 94158
- Rekrutierung
- Berkeley Outpatient Center
-
Kontakt:
- Niloufar Abdollahi
- Telefonnummer: 415.476.3322
- E-Mail: Niloufar.abdollahi@ucsf.edu
-
Hauptermittler:
- Jordan Jackson, MD
-
Kontakt:
- Dasha Peiris
- Telefonnummer: 415-533-0141
- E-Mail: Dasha.Peiris@ucsf.edu
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope -Duarte Cancer Center
-
Hauptermittler:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-Mail: mehenry@coh.org
-
Irvine, California, Vereinigte Staaten, 92618
- Rekrutierung
- City of Hope - Lennar Foundation Cancer Center
-
Hauptermittler:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-Mail: mehenry@coh.org
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- UCLA
-
Kontakt:
- Sophia Quiroz, Clinical Research Coordinator
- Telefonnummer: 310-794-0130
- E-Mail: SQuiroz@mednet.ucla.edu
-
Hauptermittler:
- Mediget Teshome, MD
-
San Francisco, California, Vereinigte Staaten, 94158
- Rekrutierung
- UCSF
-
Hauptermittler:
- Jordan Jackson, MD
-
Kontakt:
- Dasha Peiris
- Telefonnummer: 415-533-0141
- E-Mail: Dasha.Peiris@ucsf.edu
-
South Pasadena, California, Vereinigte Staaten, 91030
- Rekrutierung
- City of Hope
-
Hauptermittler:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-Mail: mehenry@coh.org
-
Walnut Creek, California, Vereinigte Staaten, 94598
- Rekrutierung
- John Muir Health
-
Kontakt:
- Jen Johnson, Clinical Research Coordinator
- Telefonnummer: 925-674-2580
- E-Mail: Jen.Johnson@johnmuirhealth.com
-
Hauptermittler:
- Monica Eigelberger, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- MedStar Washington Hospital Center
-
Hauptermittler:
- Marc Boisvert, MD
-
Kontakt:
- Hiwot Guebre-Xabiher, Research Manager
- Telefonnummer: 202-877-8839
- E-Mail: Hiwot.Guebre-Xabiher@medstar.net
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center
-
Kontakt:
- Neveen Abdo, Clinical Research Coordinator
- Telefonnummer: 727-748-9345
- E-Mail: Neveen.abdo@moffitt.org
-
Hauptermittler:
- Laura Kruper, MD
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Winship Cancer Institute, Emory University
-
Hauptermittler:
- Clara Farley, MD
-
Kontakt:
- Winship Clinical Trials Office
- Telefonnummer: 1-404-778-1868
- E-Mail: winshipcto@emory.edu
-
Kontakt:
- Trisha Burrello
- E-Mail: trisha.n.burrello@emory.edu
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Medical Center
-
Kontakt:
- Vhenyse Encarnacion
- E-Mail: vhenyse.encarnacion@bsd.uchicago.edu
-
Hauptermittler:
- Betty Fan, MD
-
-
Minnesota
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Rekrutierung
- Maple Grove Cancer Center
-
Kontakt:
- Oncology Access Nurse
- Telefonnummer: 612-624-2620
- E-Mail: ccinfo@umn.edu
-
Hauptermittler:
- Jane Hui, MD
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Rekrutierung
- University of Minnesota
-
Kontakt:
- Oncology Access Nurse
- Telefonnummer: 612-624-2620
- E-Mail: ccinfo@umn.edu
-
Hauptermittler:
- Jane Hui, MD
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Rekrutierung
- Hennepin Healthcare -Minneapolis
-
Kontakt:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-Mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-Mail: nicole.hoese@parknicollet.com
-
Hauptermittler:
- Satya Bommakanti, MD
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55426
- Rekrutierung
- Health Partners - Frauenshuh Cancer Center
-
Kontakt:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-Mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-Mail: nicole.hoese@parknicollet.com
-
Hauptermittler:
- Rachel Lerner, MD
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Health Partners - Regions Hospital
-
Kontakt:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-Mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-Mail: nicole.hoese@parknicollet.com
-
Hauptermittler:
- Rachel Lerner, MD
-
-
New Jersey
-
Englewood, New Jersey, Vereinigte Staaten, 07631
- Rekrutierung
- Englewood Hospital and Medical Center
-
Kontakt:
- Kayla Williams
- Telefonnummer: 9786 201-894-3000
- E-Mail: kayla.williams@ehmchealth.org
-
Hauptermittler:
- Jennifer Marti, MD
-
-
New York
-
New York, New York, Vereinigte Staaten, 10011
- Rekrutierung
- Mount Sinai Chelsea
-
Hauptermittler:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CRSU@mssm.edu
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Icahn School of Medicine at Mount Sinai
-
Hauptermittler:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CRSU@mssm.edu
-
New York, New York, Vereinigte Staaten, 10019
- Rekrutierung
- Mount Sinai West
-
Hauptermittler:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CRSU@mssm.edu
-
New York, New York, Vereinigte Staaten, 10003
- Rekrutierung
- Mount Sinai Union Square
-
Hauptermittler:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CRSU@mssm.edu
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Montefiore Medical Center (Hutchinson Campus Tower 1)
-
Kontakt:
- Melissa Suarez
- Telefonnummer: 718-920-6742
- E-Mail: mesuarez@montefiore.org
-
Hauptermittler:
- Sheldon Feldman, MD
-
Kontakt:
- Linda Castellanos
- Telefonnummer: 718-920-6742
- E-Mail: lcastellan@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke Cancer Institute
-
Kontakt:
- Breast Cancer Study Team
- Telefonnummer: 919-660-1278
- E-Mail: breastcl@dm.duke.edu
-
Hauptermittler:
- Ton Wang, MD
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
Hauptermittler:
- Marissa Howard-McNatt, MD
-
Kontakt:
- Brandy Baker and Lindsy Davis, RN
- Telefonnummer: 336-716-8941 OR 336-716-6748
- E-Mail: brandy.baker@advocatehealth.org, lindsey.davis@advocatehealth.org
-
Kontakt:
- Sydney McEntire
- E-Mail: sydney.mcentire@advocatehealth.org
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, Vereinigte Staaten, 19010
- Aktiv, nicht rekrutierend
- Bryn Mawr Hospital
-
Paoli, Pennsylvania, Vereinigte Staaten, 19301
- Aktiv, nicht rekrutierend
- Paoli Hospital
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- Aktiv, nicht rekrutierend
- Lankenau Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University Medical Center
-
Hauptermittler:
- Ingrid Meszoely, MD
-
Kontakt:
- Oncology nursing
- Telefonnummer: 1-800-811-8480
- E-Mail: cip@vumc.org
-
Kontakt:
- Jennifer Goodman, RN, BSN
- Telefonnummer: 615.936.6825
- E-Mail: jennifer.e.goodman@vumc.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- Huntsman Cancer Institute
-
Hauptermittler:
- Kirstyn Brownson, MD
-
Kontakt:
- Janna Espinosa
- Telefonnummer: 801-585-0571
- E-Mail: Janna.Espinosa@hci.utah.edu
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- Virginia Commonwealth University
-
Kontakt:
- Massey CTO Breast Team
- Telefonnummer: 804-628-6430
- E-Mail: masseyctbrst@vcu.edu
-
Hauptermittler:
- Kandace McGuire, MD
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
-
Hauptermittler:
- Sara Javid, MD
-
Kontakt:
- Sandra Mata-Diaz
- Telefonnummer: 206-221-3762
- E-Mail: sandramd@uw.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
A. Female, at least 18 years old
B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion
- Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.
C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial
D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.
E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.
F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant
G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment
H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent
I. Willingness and ability to provide tumor samples for research
Exclusion Criteria:
A. Pregnant or actively breastfeeding women
B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history
C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer
D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND
E. Ongoing treatment for DCIS other than what is specified in this protocol
F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements
G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures
*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)
H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment
I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.
J. Severe allergy or reaction history to MRI contrast.
K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: chemoprevention therapy per investigator choice
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally. For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years. |
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily. For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily. |
|
Experimental: Testosterone + Anastrazole (T+Ai)
White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Andere Namen:
|
|
Experimental: Elacestrant
Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months. |
|
Experimental: Endoxifen
(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patients remaining on active surveillance at 7 months
Zeitfenster: 7 months
|
Fraction of patients remaining on active surveillance at 7 months compared to control |
7 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
Zeitfenster: 6 months
|
Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
6 months
|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
Zeitfenster: 3 months
|
Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
3 months
|
|
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
Zeitfenster: 3 years
|
Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years |
3 years
|
|
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
Zeitfenster: 6 months
|
Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment) |
6 months
|
|
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
Zeitfenster: 6 months
|
Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume |
6 months
|
|
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
Zeitfenster: 6 months
|
% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density |
6 months
|
|
Determine adherence to active surveillance protocol
Zeitfenster: 5 years
|
Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index. |
5 years
|
|
Change in artificial intelligence predicted risk based on mammography
Zeitfenster: 5 years
|
Correlation of BPE change with agent and compare to quantitative imaging density |
5 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
Zeitfenster: 7 months
|
evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance |
7 months
|
|
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
Zeitfenster: 7 months
|
Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS) |
7 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
- Hauptermittler: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Brustkrebs in situ
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Adenokarzinom
- Karzinom
- Neubildungen, duktale, lobuläre und medulläre
- Karzinom in situ
- Karzinom, intraduktal, nichtinfiltrierend
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Azolen
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Steroide
- Fusions-Ring-Verbindungen
- Benzolderivate
- Nitrile
- Gonadale Steroidhormone
- Gonadalhormone
- Androstenes
- Androstanes
- Triazoles
- Stilbene
- Benzylidenverbindungen
- Androstenole
- Testosteron -Kongenere
- Letrozol
- Anastrozol
- Testosteron
- Tamoxifen
- Exemestan
- ElaCestrant
- 4-Hydroxy-n-Desmethyltamoxifen
Andere Studien-ID-Nummern
- RECAST-DCIS
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .